The Patent Finder
IP

Ionis Pharmaceuticals, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Isis Pharmaceuticals, Inc. (to 2015)

351 patents currently held

32 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
82
Ending by 2030
Dec 2026
Next term end
200
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Oligomeric Compounds Comprising 4'-Thionucleosides for Use in Gene Modulation US 7,875,733
Cited by 346 later US patents, top 1% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Ends Mar 2028 · High confidence
Also notable
Short Antisense Compounds with Gapmer Configuration US 9,045,754
Cited by 119 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Ends Apr 2028 · Low confidence
Also notable
Conjugated Antisense Compounds and Their Use US 9,127,276
Cited by 146 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than May 2034 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 30, 2026
    The maintenance fee for Methods for Modulating FMR1 Expression (US 11,661,601) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
  • 1 fee due Dec 23, 2026
    The maintenance fee for Modulation of Transthyretin Expression (US 9,061,044) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
  • 3 fees due Jan 2 to 30, 2027 · next Jan 2
  • 8 fees due Feb 1 to 22, 2027 · next Feb 1
  • 9 fees due Mar 3 to 22, 2027 · next Mar 3
  • 9 fees due Apr 1 to 22, 2027 · next Apr 1
  • 9 fees due May 3 to 24, 2027 · next May 3
  • 9 fees due Jun 3 to 30, 2027 · next Jun 3
  • 5 fees due Jul 2 to 26, 2027 · next Jul 2
  • 2 fees due Aug 11 to 25, 2027 · next Aug 11
  • 7 fees due Sep 1 to 22, 2027 · next Sep 1
  • 6 fees due Oct 14 to 26, 2027 · next Oct 14
  • 2 fees due Nov 14 to 17, 2027 · next Nov 14

Which patents, and when each one lapses · Pro

Recent changes

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,114,856Antibacterial 4,5-Substituted Aminoglycoside Analogs Having Multiple Substituents
In force
 · Medium confidence
In forceMedium confidence
US 8,569,264Antibacterial 4,5-Substituted Aminoglycoside Analogs Having Multiple Substituents
In force
 · Low confidence
In forceLow confidence
US 7,951,934Compositions and Their Uses Directed to Huntingtin
In force
 · High confidence
In forceHigh confidence
US 8,415,465Compositions and Their Uses Directed to Huntingtin
In force
 · High confidence
In forceHigh confidence
US 8,952,145Compositions and Their Uses Directed to Huntingtin
In force
 · High confidence
In forceHigh confidence
US 9,057,066Compositions and Their Uses Directed to Huntingtin
In force
 · Medium confidence
In forceMedium confidence
US 9,353,372Compositions and Their Uses Directed to Huntingtin
In force
 · High confidence
In forceHigh confidence
US 9,920,321Compositions and Their Uses Directed to Huntingtin
In force
 · High confidence
In forceHigh confidence
US 10,655,129Compositions and Their Uses Directed to Huntingtin
In force
 · High confidence
In forceHigh confidence
US 10,738,307Compositions and Their Uses Directed to Huntingtin
In force
 · Medium confidence
In forceMedium confidence
10 of 351 patents shown.
Pro members see all 351.
Pro members: see all 351 patents
Also on record, not counted in the 351: 32 patents in force now held by others · 196 patents ended · 141 applications pending · 234 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited